PRAXIS PRECISION MEDICINES, INC. PRAX 深 滬
等待開盤 08-06 09:30:00 美东时间
47.79
-3.300
-6.46%
華盛通- 最 高53.46
- 今 開53.05
- 成交量 86.58万股
- 最 低 46.575
- 昨 收 51.09
- 總市值 9.73亿
- 52周最高 91.83
- 市盈率 靜 --
- 換手率 4.25%
- 52周最低 26.70
- 委 比 44.44%
- 總股本 2036.90万
- 歷史最高 914.265
- 量 比 1.08
- 振 幅 13.48%
- 歷史最低 11.85
- 每 手 1
- 風險率 16.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures.
08-05 01:38
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines, a clinical-stage biopharmaceutical company focusing on developing therapies for CNS disorders, announced that its CEO Marcio Souza will participate in a virtual fireside chat hosted by analyst Joon Lee from Truist Securities on August 5, 2025 at 10:00am EST. Registration details are available via the provided link. The company translates genetic insights into innovative treatments for neuronal excitation-inhibition imb...
08-05 00:24
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Praxis Precision Medicines reported positive results from the RADIANT study for vormatrigine in focal onset seizures, showing a 56.3% reduction in seizure frequency and 22% of patients achieving 100% seizure reduction. The company also initiated registrational studies for its developmental epilepsy programs, including EMERALD for relutrigine and EMBRAVE3 for elsunersen. Relutrigine received FDA Breakthrough Therapy Designation for seizures associ...
08-04 12:30
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
VRTX-805在治疗硬斑瘤的II期临床试验中显示，48周后，纤维化程度减少47%，斑块负荷减轻39%。研究结果表明VRTX-805对早期疾病患者效果更为显著，NIAH评分下降37%。治疗反应在24周时即可观察到，并且在随访期间持续改善（最长2.5年随访）。VRTX-805表现出良好的安全性，无赛庚啶相关不良事件报告。
08-04 12:00
Praxis Home Retail Sets Schedule for Rights Issue
Praxis Home Retail Ltd. ( ($IN:PRAXIS) ) has provided an update. Praxis Home Re...
07-31 04:57
Chardan Capital Maintains Buy on Praxis Precision Medicine, Maintains $80 Price Target
Chardan Capital analyst Rudy Li maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $80 price target.
07-29 18:45
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
Praxis Precision Medicines will report RADIANT trial results and second-quarter financial data on August 4, 2025. A live webcast will discuss findings at 8:30am ET. The company focuses on developing CNS therapies using genetic insights into neuronal imbalance.
07-29 12:00
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
The FDA has granted Breakthrough Therapy Designation (BTD) to relutrigine for treating pediatric SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). This decision follows compelling results from the Phase 2 EMBOLD trial, showing a 90% average reduction in seizures and prolonged seizure-free periods. Topline results from the pivotal EMBOLD cohort 2 are expected in H1 2026, with an NDA filing to follow. Additionally, the EMERALD st...
07-17 12:00
美股大行评级 | 潜在涨幅687%！ 花旗上调新氧科技目标价升至5.5美元，评级"买入"
今日重点评级关注：B. Riley证券：维持内克塔治疗"买入"评级，目标价从60美元升至85美元；Oppenheimer：维持Praxis Precision Medicine"跑赢大市"评级，目标价从97美元升至115美元
07-09 09:26
